On July 13, 2026 VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, reported a collaboration with Ardigen S.A., an AI-driven computational partner for modern R&D recognized for pioneering the use of artificial intelligence (AI) and bioinformatics for precision medicine, to support VERAXA’s growing BiTAC pipeline of t cell engagers (TCEs) and antibody drug conjugates (ADCs). The collaboration is another milestone in VEREXA’s mission to integrate AI into its research and development, with the long-term goal to achieve success rates in drug development that exceed industry benchmarks.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Current high-potency modalities, including TCEs and ADCs, are frequently limited by severe on-target, off-tumor toxicities, restricting therapeutic efficacy and leading to high failure rates in development. VERAXA’s BiTAC-TCEs and future BiTAC-ADCs utilize a Boolean "AND-gate" logic, requiring the co-expression of two distinct targets on the same cancer cell for activation. This innovative approach has the potential to significantly widen the therapeutic window by sparing healthy tissues and even systemic toxicity.
With the BiTAC platform, VERAXA believes that it can leverage the extensive body of existing preclinical and clinical data generated across the industry, particularly from programs that failed due to toxicity despite demonstrating promising efficacy. AI could enable the integration and analysis of such large datasets to identify improved dual-target combinations, refine therapeutic design, and potentially rescue previously challenging or "undruggable" targets. The partnership with Ardigen will initially focus on developing AI-enabled tools and models to guide the selection process of synergistic cancer target pairs for VERAXA’s growing BiTAC portfolio.
"We see enormous potential in the application of AI processes to help guide the development strategy of our proprietary BiTAC programs," commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. "Because of the nature of BiTACs, smart cancer target selection and thorough validation from the outset can have a transformative impact on future success rates and product profiles. This collaboration represents a strategic step forward in harnessing the power of AI to bring precision oncology therapies to patients faster."
(Press release, Veraxa Biotech, JUL 13, 2026, View Source [SID1234669184])